MetaVia Unveils Promising DA-1241 Trial Results

MetaVia ( (MTVA) ) has shared an announcement.

On May 7, 2025, MetaVia Inc. presented data from its Phase 2a clinical trial of DA-1241 at the European Association for the Study of the Liver Congress 2025 in Amsterdam. The trial demonstrated that DA-1241, a G-Protein-Coupled Receptor 119 agonist, has hepatoprotective and glucose-regulating effects in patients with presumed MASH. The study showed significant improvements in liver health markers and glycemic control, suggesting DA-1241’s potential as a multifaceted treatment for progressive liver disease. DA-1241 was well tolerated, and the results support its further development as a monotherapy or combination therapy for MASH and metabolic diseases.

Spark’s Take on MTVA Stock

According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.

MetaVia’s overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock’s high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.

To see Spark’s full report on MTVA stock, click here.

More about MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Average Trading Volume: 509,570

Technical Sentiment Signal: Sell

Current Market Cap: $7.47M

Find detailed analytics on MTVA stock on TipRanks’ Stock Analysis page.